Mesoblast (MEOBF) furnishes ASX press release to U.S. investors via Form 6-K

Rhea-AI Filing Summary

Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer. The report forwards a news release announcement that Mesoblast filed with the Australian Securities Exchange on November 5, 2025, attaching it as Exhibit 99.1 and incorporating it by reference.

The filing is signed on behalf of Mesoblast Limited by Company Secretary Paul Hughes, dated November 5, 2025.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On November 5, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Paul Hughes

Paul Hughes

Company Secretary

Dated: November 5, 2025

INDEX TO EXHIBITS

Item
99.1						Press release of Mesoblast Ltd, dated November 5, 2025.

FAQ

What does Mesoblast Limited (MEOBF) disclose in this Form 6-K?

Mesoblast Limited uses this Form 6-K to provide U.S. investors with a news release it filed on the Australian Securities Exchange on November 5, 2025, attaching that announcement as Exhibit 99.1 and incorporating it into the report by reference.

What is the purpose of Mesoblast’s November 2025 Form 6-K filing?

The purpose is to furnish a Mesoblast news release previously filed with the Australian Securities Exchange. By attaching the announcement as Exhibit 99.1, Mesoblast makes the same information available to U.S. markets under the Securities Exchange Act framework for foreign private issuers.

Who signed the November 5, 2025 Mesoblast (MEOBF) Form 6-K?

The Form 6-K is signed on behalf of Mesoblast Limited by Paul Hughes, the Company Secretary. His signature confirms that the company has duly caused the report to be submitted under the requirements of the Securities Exchange Act of 1934.

What exhibit is included with Mesoblast Limited’s November 2025 Form 6-K?

The filing includes one exhibit, labeled 99.1. This exhibit is described as a press release of Mesoblast Ltd dated November 5, 2025, which was originally filed with the Australian Securities Exchange and is incorporated into the Form 6-K by reference.

How does Mesoblast (MEOBF) use the ASX press release in this U.S. filing?

Mesoblast attaches the Australian Securities Exchange news release as Exhibit 99.1 to its Form 6-K. The company states that this announcement, filed on November 5, 2025, is incorporated by reference, extending the same disclosure to U.S. investors and regulators.

What type of issuer is Mesoblast Limited in this Form 6-K?

Mesoblast Limited files this report as a foreign private issuer incorporated in Australia. The Form 6-K notes that the company provides information to U.S. markets under the Securities Exchange Act framework that applies to foreign private issuers reporting using Form 20-F style disclosure.